Baumer: peers
Baumer beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Baumer, Seyitler Kimya Sanayi A.S., TTBIO Corp.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Baumerbase BALM4.SA · 🇧🇷 BR Percentile in Healthcare Percentile in Brazil | Retractable Technologies, Inc. RVP · 🇺🇸 US Percentile in Healthcare Percentile in USA | Milestone Scientific Inc. MLSS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Femasys Inc. FEMY · 🇺🇸 US Percentile in Healthcare Percentile in USA | Nephros, Inc. NEPH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Harvard Bioscience, Inc. HBIO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Seyitler Kimya Sanayi A.S. SEYKM.IS · 🇹🇷 TR Percentile in Healthcare Percentile in Turkey | TTBIO Corp. 6493.TWO · 🇹🇼 TW Percentile in Healthcare Percentile in Taiwan | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $20 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one4th of 8 | $18 MOct 28, 2026 · Market data7th of 8 | $31 MOct 14, 2026 · Market data3rd of 8 | $12 MOct 29, 2026 · Market data8th of 8 | $36 MOct 30, 2026 · Market data2nd of 8 | $38 MOct 26, 2026 · Market data1st of 8 | $20 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8 | $20 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one4th of 8 | $20 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $38 MFY2025 · SEC2nd of 5 | $9 MFY2025 · SEC4th of 5 | $2 MFY2025 · SEC5th of 5 | $19 MFY2025 · SEC3rd of 5 | $87 MFY2025 · SEC1st of 5 | —— | —— | $19 M5 ranked |
| Net income (Higher is better) | —— | $-13 MFY2025 · SEC3rd of 5 | $-6 MFY2025 · SEC2nd of 5 | $-19 MFY2025 · SEC4th of 5 | $1 MFY2025 · SEC1st of 5 | $-57 MFY2025 · SEC5th of 5 | —— | —— | $-13 M5 ranked |
| Employees (Better neither way: ranked highest first) | —— | 201March 9, 2026 · Profile1st of 4 | 15December 31, 2025 · Profile4th of 4 | 51December 31, 2025 · Profile2nd of 4 | 36December 31, 2025 · Profile3rd of 4 | —— | —— | —— | 444 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +15.8%FY2025 · SEC3rd of 560th73rd | +3.9%FY2025 · SEC4th of 534th42nd | +40.5%FY2025 · SEC1st of 582nd90th | +32.7%FY2025 · SEC2nd of 578th87th | -8.1%FY2025 · SEC5th of 515th13th | ———— | ———— | +15.8%5 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | -26.1%FY2025 · SEC5th of 56th2nd | +0.6%FY2025 · SEC3rd of 529th35th | +23.7%FY2025 · SEC1st of 576th88th | +23.5%FY2025 · SEC2nd of 576th88th | -8.6%FY2025 · SEC4th of 514th12th | ———— | ———— | +0.6%5 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | +1000.0%FY2025 · SEConly one with it100th100th | ———— | ———— | ———— | +1000.0%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 0.1%FY2025 · SEC5th of 52nd2nd | 71.5%FY2025 · SEC1st of 570th84th | 62.0%FY2025 · SEC2nd of 555th76th | 61.8%FY2025 · SEC3rd of 555th76th | 57.7%FY2025 · SEC4th of 549th72nd | ———— | ———— | 61.8%5 ranked |
| Operating margin (Higher is better) | ———— | -55.3%FY2025 · SEC2nd of 530th14th | -63.5%FY2025 · SEC4th of 528th13th | -768.1%FY2025 · SEC5th of 52nd1st | 6.1%FY2025 · SEC1st of 567th59th | -56.1%FY2025 · SEC3rd of 530th14th | ———— | ———— | -56.1%5 ranked |
| Net margin (Higher is better) | ———— | -32.9%FY2025 · SEC2nd of 536th17th | -63.8%FY2025 · SEC3rd of 528th13th | -813.5%FY2025 · SEC5th of 52nd1st | 6.3%FY2025 · SEC1st of 572nd65th | -65.5%FY2025 · SEC4th of 528th12th | ———— | ———— | -63.8%5 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | -32.8%FY2025 · SEC2nd of 332nd14th | -839.3%FY2025 · SEC3rd of 32nd1st | ———— | 6.3%FY2025 · SEC1st of 365th59th | ———— | ———— | -32.8%3 ranked |
| Return on equity (Higher is better) | ———— | -15.6%FY2025 · SEC2nd of 563rd30th | -132.4%FY2025 · SEC3rd of 518th8th | -456.1%FY2025 · SEC5th of 52nd1st | 12.7%FY2025 · SEC1st of 585th73rd | -147.1%FY2025 · SEC4th of 516th7th | ———— | ———— | -132.4%5 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 18.7×price Oct 30, 2026 · Market dataonly one with it29th49th | ———— | ———— | ———— | 18.7×— |
| Price to sales (Better neither way: ranked highest first) | ———— | 0.5×price Oct 28, 2026 · Market data4th of 58th16th | 3.3×price Oct 14, 2026 · Market data2nd of 546th64th | 5.3×price Oct 29, 2026 · Market data1st of 558th79th | 1.6×price Oct 30, 2026 · Market data3rd of 528th43rd | 0.4×price Oct 26, 2026 · Market data5th of 57th13th | ———— | ———— | 1.6×5 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 0.2×price Oct 28, 2026 · Market data5th of 52nd2nd | 11.0×price Oct 14, 2026 · Market data1st of 585th90th | 2.1×price Oct 29, 2026 · Market data4th of 539th49th | 3.5×price Oct 30, 2026 · Market data2nd of 555th67th | 2.7×price Oct 26, 2026 · Market data3rd of 546th59th | ———— | ———— | 2.7×5 ranked |
| Free cash flow yield (Higher is better) | ———— | -73.6%price Oct 28, 2026 · Market data4th of 511th4th | -9.5%price Oct 14, 2026 · Market data3rd of 543rd21st | -157.4%price Oct 29, 2026 · Market data5th of 53rd1st | -1.6%price Oct 30, 2026 · Market data2nd of 563rd33rd | 14.5%price Oct 26, 2026 · Market data1st of 597th93rd | ———— | ———— | -9.5%5 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | 0.0×FY2025 · SEC1st of 210th7th | ———— | ———— | ———— | 2.6×FY2025 · SEC2nd of 291st89th | ———— | ———— | 1.3×2 ranked |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | ———— | -37.4×FY2025 · SEConly one with it25th11th | ———— | ———— | -37.4×— |
| Piotroski F-score (Higher is better) | —— | 4 of 9FY2025 · SEC2nd of 2 | —— | —— | —— | 5 of 9FY2025 · SEC1st of 2 | —— | —— | 4.5 of 92 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 7 of 22FY2025 · Scorecard3rd of 5 | 4 of 20FY2025 · Scorecard5th of 5 | 7 of 20FY2025 · Scorecard2nd of 5 | 12 of 21FY2025 · Scorecard1st of 5 | 6 of 23FY2025 · Scorecard4th of 5 | —— | —— | 32% passed5 ranked |
| Valuation checks (Higher is better) | —— | 2 of 5FY2025 · Scorecard3rd of 5 | 0 of 5FY2025 · Scorecard5th of 5 | 1 of 5FY2025 · Scorecard4th of 5 | 4 of 6FY2025 · Scorecard1st of 5 | 3 of 6FY2025 · Scorecard2nd of 5 | —— | —— | 40% passed5 ranked |
| Growth checks (Higher is better) | —— | 1 of 6FY2025 · Scorecard4th of 5 | 2 of 6FY2025 · Scorecard3rd of 5 | 4 of 6FY2025 · Scorecard2nd of 5 | 5 of 6FY2025 · Scorecard1st of 5 | 0 of 6FY2025 · Scorecard5th of 5 | —— | —— | 33% passed5 ranked |
| Profitability checks (Higher is better) | —— | 0 of 5FY2025 · Scorecard4th of 5 | 1 of 5FY2025 · Scorecard2nd of 5 | 1 of 5FY2025 · Scorecard2nd of 5 | 2 of 5FY2025 · Scorecard1st of 5 | 0 of 5FY2025 · Scorecard4th of 5 | —— | —— | 20% passed5 ranked |
| Financial health checks (Higher is better) | —— | 3 of 5FY2025 · Scorecard1st of 5 | 1 of 3FY2025 · Scorecard3rd of 5 | 1 of 3FY2025 · Scorecard3rd of 5 | 1 of 3FY2025 · Scorecard3rd of 5 | 2 of 5FY2025 · Scorecard2nd of 5 | —— | —— | 33% passed5 ranked |
| Shareholder returns checks (Higher is better) | —— | 1 of 1FY2025 · Scorecard1st of 5 | 0 of 1FY2025 · Scorecard3rd of 5 | 0 of 1FY2025 · Scorecard3rd of 5 | 0 of 1FY2025 · Scorecard3rd of 5 | 1 of 1FY2025 · Scorecard1st of 5 | —— | —— | 0% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 8.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5 | 5.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 5 | 78.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5 | 23.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5 | 30.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5 | —— | —— | 23.7%5 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5 | 322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5 | 272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 5 | 362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5 | 302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5 | —— | —— | 325 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | +0.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 4 | -0.3 pp2026-Q2 against 2026-Q1 · 13F3rd of 4 | —— | -1.5 pp2026-Q2 against 2026-Q1 · 13F4th of 4 | +26.7 pp2026-Q2 against 2026-Q1 · 13F1st of 4 | —— | —— | +0.1 pp4 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Baumer: How market caps are worked out; Retractable Technologies, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Milestone Scientific Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Femasys Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nephros, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Harvard Bioscience, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Seyitler Kimya Sanayi A.S.: How market caps are worked out; TTBIO Corp.: Taiwan Stock Exchange and Taipei Exchange, issued shares times the close.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Baumer | — | — | — |
| Retractable Technologies, Inc. | -55.3%FY2025 | 30th percentile in Healthcaremedian -7.7%, 674 companies | 14th percentile in USAmedian 3.5%, 2,594 companies |
| Milestone Scientific Inc. | -63.5%FY2025 | 28th percentile in Healthcaremedian -7.7%, 674 companies | 13th percentile in USAmedian 3.5%, 2,594 companies |
| Femasys Inc. | -768.1%FY2025 | 2nd percentile in Healthcaremedian -7.7%, 674 companies | 1st percentile in USAmedian 3.5%, 2,594 companies |
| Nephros, Inc. | 6.1%FY2025 | 67th percentile in Healthcaremedian -7.7%, 674 companies | 59th percentile in USAmedian 3.5%, 2,594 companies |
| Harvard Bioscience, Inc. | -56.1%FY2025 | 30th percentile in Healthcaremedian -7.7%, 674 companies | 14th percentile in USAmedian 3.5%, 2,594 companies |
| Seyitler Kimya Sanayi A.S. | — | — | — |
| TTBIO Corp. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Baumer | Retractable Technologies, Inc. | Milestone Scientific Inc. | Femasys Inc. | Nephros, Inc. | Harvard Bioscience, Inc. | Seyitler Kimya Sanayi A.S. | TTBIO Corp. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $38 MSEC2nd | $9 MSEC4th | $2 MSEC5th | $19 MSEC3rd | $87 MSEC1st | — | — |
| 2024 | — | $33 MSEC2nd | $9 MSEC4th | $2 MSEC5th | $14 MSEC3rd | $94 MSEC1st | — | — |
| 2023 | — | $44 MSEC2nd | $10 MSEC4th | $1 MSEC5th | $14 MSEC3rd | $112 MSEC1st | — | — |
| 2022 | — | $95 MSEC2nd | $9 MSEC4th | $1 MSEC5th | $10 MSEC3rd | $113 MSEC1st | — | — |
| 2021 | — | $188 MSEC1st | $10 MSEC3rd | $1 MSEC5th | $10 MSEC4th | $119 MSEC2nd | — | — |
| 2020 | — | $82 MSEC2nd | $5 MSEC4th | $1 MSEC5th | $9 MSEC3rd | $102 MSEC1st | — | — |
| 2019 | — | $42 MSEC2nd | $8 MSEC4th | — | $10 MSEC3rd | $116 MSEC1st | — | — |
| 2018 | — | $33 MSEC2nd | $10 MSEC3rd | — | $6 MSEC4th | $121 MSEC1st | — | — |
| 2017 | — | $34 MSEC2nd | $11 MSEC3rd | — | $4 MSEC4th | $77 MSEC1st | — | — |
| 2016 | — | $30 MSEC2nd | $10 MSEC3rd | — | $2 MSEC4th | $105 MSEC1st | — | — |
| 2015 | — | $30 MSEC2nd | $9 MSEC3rd | — | $2 MSEC4th | $109 MSEC1st | — | — |
| 2014 | — | $35 MSEC2nd | $10 MSEC3rd | — | $2 MSEC4th | $109 MSEC1st | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Baumer#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Retractable Technologies, Inc.RVP · 🇺🇸 USASame industry: Medical Instruments · Similar size: $18 M market cap against $20 M · Ratios of the last two fiscal years on fileMarket cap $18 M (Oct 28, 2026) · revenue $38 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Milestone Scientific Inc.MLSS · 🇺🇸 USASame industry: Medical Instruments · Similar size: $31 M market cap against $20 M · Ratios of the last two fiscal years on fileMarket cap $31 M (Oct 14, 2026) · revenue $9 M (year to December 2025)82 of 100 (industry or sector 50 + size 27 + figures on file 5)In the group
- Femasys Inc.FEMY · 🇺🇸 USASame industry: Medical Instruments · Similar size: $12 M market cap against $20 M · Ratios of the last two fiscal years on fileMarket cap $12 M (Oct 29, 2026) · revenue $2 M (year to December 2025)82 of 100 (industry or sector 50 + size 27 + figures on file 5)In the group
- Nephros, Inc.NEPH · 🇺🇸 USASame industry: Medical Instruments · Similar size: $36 M market cap against $20 M · Ratios of the last two fiscal years on fileMarket cap $36 M (Oct 30, 2026) · revenue $19 M (year to December 2025)81 of 100 (industry or sector 50 + size 26 + figures on file 5)In the group
- Harvard Bioscience, Inc.HBIO · 🇺🇸 USASame industry: Medical Instruments · Similar size: $38 M market cap against $20 M · Ratios of the last two fiscal years on fileMarket cap $38 M (Oct 26, 2026) · revenue $87 M (year to December 2025)81 of 100 (industry or sector 50 + size 26 + figures on file 5)In the group
- Seyitler Kimya Sanayi A.S.SEYKM.IS · 🇹🇷 TurkeySame industry: Medical Instruments · Similar size: $20 M market cap against $20 MMarket cap $20 M (last known, Jan 5, 2024)80 of 100 (industry or sector 50 + size 30)In the group
- TTBIO Corp.6493.TWO · 🇹🇼 TaiwanSame industry: Medical Instruments · Similar size: $20 M market cap against $20 MMarket cap $20 M (last known, Jul 30, 2023)80 of 100 (industry or sector 50 + size 30)In the group
- Sona Nanotech Inc.SONA.CN · 🇨🇦 CanadaSame industry: Medical Instruments · Similar size: $20 M market cap against $20 MMarket cap $20 M (last known, Jan 5, 2024)80 of 100 (industry or sector 50 + size 30)+ Add
- Comfort Gloves Berhad2127.KL · 🇲🇾 MalaysiaSame industry: Medical Instruments · Similar size: $21 M market cap against $20 MMarket cap $21 M (Aug 1, 2026)80 of 100 (industry or sector 50 + size 30)+ Add
- Sincere Co., Ltd.7782.T · 🇯🇵 JapanSame industry: Medical Instruments · Similar size: $19 M market cap against $20 MMarket cap $19 M (last known, Mar 8, 2026)80 of 100 (industry or sector 50 + size 30)+ Add
- Kaisa Health Group Holdings Limited0876.HK · 🇭🇰 Hong KongSame industry: Medical Instruments · Similar size: $23 M market cap against $20 MMarket cap $23 M (last known, Jan 5, 2024)79 of 100 (industry or sector 50 + size 29)+ Add
- Elegance Optical International Holdings Limited0907.HK · 🇭🇰 Hong KongSame industry: Medical Instruments · Similar size: $17 M market cap against $20 MMarket cap $17 M (last known, Jan 5, 2024)79 of 100 (industry or sector 50 + size 29)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.